Swiss pharmaceutical company Roche has announced that a new antibiotic, zosurabalpin, is progressing to phase 3 testing.

A groundbreaking antibiotic discovery might finally tip the balance in the global fight against drug-resistant bacteria.

Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure ...

Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had ...

The British drugmaker may have succeeded in reviving an oral antibiotic previously rejected by the FDA when it was under ...

Obesity can have a distinct impact on the absorption, effectiveness and excretion of antibiotics, medications that have been ...

Roche is planning to move a new antibiotic into late-stage clinical trials after studies showed it had potential to tackle a ...

The approval of brensocatib for use in patients with bronchiectasis could offer the first treatment directly addressing the ...

Roche is moving its novel antibiotic zosurabalpin into phase 3 testing for carbapenem-resistant Acinetobacter baumannii (CRAB), a 'superbug' that is considered an 'urgent threat' by the CDC, in what ...

Scientists at Roche and Harvard University have discovered an entirely new class of antibiotic that can kill a highly drug-resistant ‘superbug’ with a mortality rate that can be upwards of 50% ...

More than $300 million in grant money promised to UCI, UCLA, USC and dozens of other California institutions has been axed ...